Following a meta-analysis of the gene expression profiles of a total of 1,107 tumors combined with a further analysis of two single datasets, Faratian et al. [132] reported in 2011 that Spry1, Spry2, and Spry4 were differentially expressed across clinicopathological subgroups of the breast cancer and that low Spry2 expression was associated with high expression of the human epidermal growth factor receptor 2 gene (HER2). This evidence concerns the gene SPRY2 and breast carcinoma.